Navigation Links
DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM) FA for the Treatment of DME
Date:10/17/2007

ith Pfizer Inc. for other ophthalmic applications of the Durasert(TM) technology which underpins the Medidur product.

pSivida owns the rights to develop and commercialize a modified form of silicon (porosified or nano-structured silicon) known as BioSilicon(TM), which has applications in drug delivery, wound healing, orthopedics, and tissue engineering. The most advanced BioSilicon(TM) product, BrachySil(TM) delivers a therapeutic, P32 directly to solid tumors and is presently in Phase II clinical trials for the treatment of pancreatic cancer. For more information, please visit http://www.psivida.com

Various statements made in this release are forward-looking and involve a number of risks and uncertainties. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements. The following are some of the factors that could cause actual results to differ materially from the forward-looking statements: the risks that we will not be able to raise additional capital; that we will continue to incur losses and may never become profitable; that we will be required to pay penalties pursuant to registration agreements with securities holders and not have sufficient funds to do so; that we will be unable to develop new products; that we will be unable to protect our own intellectual property or will infringe on others' intellectual property; that we will not receive regulatory approvals necessary to commercialize products; that we will be unable to secure partners necessary to develop and market products; that our current licensees will terminate their agreements with us; that our competitors' products will receive regulatory approval before, reach the market before, or otherwise receive better market acceptance than, our product candidates; that our international business operations will result in increased costs or delays; that m
'/>"/>

SOURCE Alimera Sciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Vitamin E supports Female Hearts
2. Injection supports Heart Devices
3. Study supports vegetable diet
4. Study supports century-old cancer theory
5. Google Supports Indians Novel Literacy Drive
6. Actor Anil Kapoor Supports Birth Registration Cause
7. AMA Supports Tax Penalty for Uninsured Americans
8. Church Supports HIV Test Before Marriage
9. EHRVA Supports EHR Product Certification
10. NICE supports application of advanced biological therapies as treatment option for acute psoriasis
11. Bush Supports Restriction to ‘Morning–After’ Pll
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2015)... Vancouver personal injury lawyers at Jiwa Law Corporation recently ... limits. They stated that in many cases, missing an important ... it. Many a time, delays in making an injury claim ... law. As a result, experts at Jiwa Law Corporation suggest ... personal injury lawyer in order to know more about their ...
(Date:2/28/2015)... Pioneer Millworks reclaimed USA wood will be on ... Show, an annual, premier sustainable building event in Tokyo, ... manufacturers of the latest building products, services and technology. ... manufactured by Pioneer Millworks from their Oregon and New ... hotels, retailers, and corporate offices. Nichibi Global , ...
(Date:2/28/2015)... 2015 Kaylie Corrigan, Outdoor Supervisor at ... , and current student obtaining her Masters degree in ... weekly forum in psychoeducation on substance use for teens ... as part of her studies. , “Even though these ... and counseling at the high school and junior high ...
(Date:2/28/2015)... 28, 2015 Developers of FCPX ... new overlay plugin for Final Cut Pro X entitled FCPX ... Overlay Chromatic gives users total control over 6k lens dirt ... of Pixel Film Studios. “FCPX Overlay Chromatic was professionally designed ... use interface.” , FCPX Overlay Chromatic Grunge 6K is a ...
(Date:2/28/2015)... 2015 The World Scout League Commission ... to potential EMTs and firefighters, recently announced its decision ... way to raise charitable donations for age-related research. The ... will be held on March 29, 2015; registration will ... at 3:30 p.m. , To participate in the ...
Breaking Medicine News(10 mins):Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2Health News:Pixel Film Studios released a new overlay plugin entitled FCPX Overlay Chromatic Grunge 6K exclusively for Final Cut Pro X users 2Health News:Bitcoin Run Is The World Scout League Commission’s Newest Project for Charity 2
... SAN JOSE, Calif., Dec. 28 For the majority of Americans ... New Year brings mixed emotions: the renewed resolution to shed pounds ... those goals. Helping to bridge the gap between resolutions and reality, ... an unexpected nutritious punch. , Mushrooms are one such example - ...
... thought to occur at the synapse, since synapse loss ... amyloid beta (Aβ) plays an important role in early ... effect on the plasticity of dendritic spines. ... neurons) that relay electrical impulses in the brain. A ...
... biggest factor standing in people,s way , MONDAY, Dec. 28 (HealthDay ... Americans will resolve that this year, they,ll exercise ... so many of those resolutions broken? , New research may shed ... know that exercise is good for them and can improve their ...
... 28 Former NY Giant great and NFL Hall of ... the Year Award for Chiropractic in New York State for ... honor at the NY Chiropractic Council,s annual convention in Tarrytown, ... instrumental in leading H.O.P.E. Day, which stands for Helping Other ...
... CAQH® announced today that Aetna and WellPoint, together ... health plans to earn certification for electronically exchanging administrative ... Information Exchange® (CORE) Phase II rules. , Aetna ... of the CORE rules, which represent an all-payer solution ...
... only one sibling affected , MONDAY, Dec. 28 (HealthDay ... as diet and chemical exposure may play a role ... , American and Spanish researchers compared the DNA of ... that can influence the expression of genes) in healthy ...
Cached Medicine News:Health News:Pack Meals With Superfoods to Maximize Healthy Resolutions 2Health News:Pack Meals With Superfoods to Maximize Healthy Resolutions 3Health News:Pack Meals With Superfoods to Maximize Healthy Resolutions 4Health News:How amyloid beta reduces plasticity related to synaptic signaling 2Health News:Top Reasons Those 'Get Fit' Resolutions Don't Stick 2Health News:Top Reasons Those 'Get Fit' Resolutions Don't Stick 3Health News:All-Time Giant Great Receives Humanitarian of the Year Award 2Health News:Aetna and WellPoint Achieve CORE Phase II Certification 2Health News:Aetna and WellPoint Achieve CORE Phase II Certification 3
(Date:2/27/2015)... LEXINGTON, Mass. , Feb. 27, 2015   ... GEVA ), a biopharmaceutical company developing therapeutic products ... Rare Disorders™ (NORD™), the European Organisation for Rare ... around the world in observing Rare Disease Day. ... each year, patient organizations, industry, and other participants ...
(Date:2/27/2015)... 2015  PTC Therapeutics, Inc. (NASDAQ: PTCT ... results for the fourth quarter and full year ended ... transformative year for PTC. We are now a growing ... therapies in the rare disease space," stated Stuart W. ... are proud to bring the first treatment for Duchenne ...
(Date:2/27/2015)... , Feb. 27, 2015  Uroplasty, Inc. (NASDAQ: ... and markets innovative proprietary products to treat voiding dysfunctions, ... Annual ROTH Conference on Tuesday, March 10, 2015. ... Reynolds , Chief Financial Officer, will present at 4:00 ... one at the conference at the Ritz Carlton in ...
Breaking Medicine Technology:Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Uroplasty to Participate in the 27th Annual ROTH Conference 2
... 15 VION,PHARMACEUTICALS, INC. (Nasdaq: VION ) today ... to the pivotal Phase II trial of its lead ... novo poor-risk acute myelogenous leukemia (AML). Alan Kessman, ... reached this milestone in the pivotal Phase II trial ...
... Study to Explore the Efficacy of Novel Proteasome Inhibitor ... Patients with Relapsed and Refractory Multiple Myeloma, SOUTH ... Multiple Myeloma Research Consortium (MMRC) and Proteolix, Inc. today,announced ... Phase 2,clinical trial to study Proteolix,s potent and selective ...
Cached Medicine Technology:Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 2Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 3Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 4The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 2The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 3The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 4
Latex agglutination test for the qualitative and semiquantitative determination of rheumatoid factor in serum....
The SYNCHRON CX3 Delta is a critical care clinical system, providing unparalleled testing speed for the most frequently ordered chemistries-Glucose, BUN, Creatinine, Sodium, Potassium Chloride, CO2 C...
The Rheumatoid Factor (RF) assay is used for the quantitative analysis of rheumatoid factor in human serum....
... choosing a non-contact diagnostic lens, doctors have to ... view and high magnification. Now, with the ... Optical, doctors can have both in one lens. ... view available in a non-contact lens paired with ...
Medicine Products: